BioVentrix

About BioVentrix

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

```xml <problem> Ischemic cardiomyopathy leads to congestive heart failure due to the enlargement and impaired function of the left ventricle. Current treatments do not directly address the anatomical damage to the heart muscle, limiting their effectiveness in restoring cardiac function. </problem> <solution> BioVentrix develops surgical equipment designed to restore the size and function of the left ventricle in patients with ischemic cardiomyopathy. Their technology aims to directly address the anatomical damage caused by the disease, improving cardiac function and potentially slowing the progression of heart failure. By reshaping the left ventricle, the device helps the heart pump more efficiently, leading to improved patient outcomes. </solution> <features> - Surgical device for left ventricular restoration. - Aims to improve cardiac function in patients with ischemic cardiomyopathy. - Addresses anatomical damage to the heart muscle. </features> <target_audience> The primary target audience includes cardiac surgeons and patients suffering from heart failure due to ischemic cardiomyopathy. </target_audience> ```

What does BioVentrix do?

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

Where is BioVentrix located?

BioVentrix is based in Mansfield, United Kingdom.

When was BioVentrix founded?

BioVentrix was founded in 2003.

How much funding has BioVentrix raised?

BioVentrix has raised $48.5M.

Who founded BioVentrix?

BioVentrix was founded by David Richmond.

  • David Richmond - CEO
Location
Mansfield, United Kingdom
Founded
2003
Funding
$48.5M
Employees
18 employees
Major Investors
Andera Partners
B

BioVentrix

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

Mansfield, United KingdomFounded 2003183K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 20 months ago

Funding

$48.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

AP
Funding rounds are not available yet.

Founders

Product

Problem

Ischemic cardiomyopathy leads to congestive heart failure due to the enlargement and impaired function of the left ventricle. Current treatments do not directly address the anatomical damage to the heart muscle, limiting their effectiveness in restoring cardiac function.

Solution

BioVentrix develops surgical equipment designed to restore the size and function of the left ventricle in patients with ischemic cardiomyopathy. Their technology aims to directly address the anatomical damage caused by the disease, improving cardiac function and potentially slowing the progression of heart failure. By reshaping the left ventricle, the device helps the heart pump more efficiently, leading to improved patient outcomes.

Target Audience

The primary target audience includes cardiac surgeons and patients suffering from heart failure due to ischemic cardiomyopathy.

Features

  • Surgical device for left ventricular restoration.
  • Aims to improve cardiac function in patients with ischemic cardiomyopathy.
  • Addresses anatomical damage to the heart muscle.
1
This profile is AI-generated and may contain inaccuracies.